Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Fei Tang, Xuexiang Du, Mingyue Liu, Pan Zheng, Yang Liu

ABSTRACT

Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of naïve T cells in the lymphoid organs. Recently, we reported that anti-CTLA-4 antibody Ipilimumab effectively induces tumor rejection in vivo although it blocks neither B7 transendocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Using genetic model in which the anti-CTLA-4 antibodies are unable to engage more than 50% of CTLA-4, we demonstrated that saturating binding of CTLA-4 is not necessary for tumor rejection. Our results argue against B7-CTLA-4 blockade as the mechanism of action for the clinically effective Ipilimumab. Moreover, Ipilimumab induces tumor rejection even in the absence of de novo T cell priming in the lymphoid organs. Thus, our data are inconsistent with key provisions of the prevailing hypothesis on mechanism of action by anti-CTLA-4 antibodies. Furthermore, anti-CTLA-4 antibodies effectively induce depletion of regulatory T (Treg) cells in tumor microenvironment but not in the peripheral lymphoid organs, which is strictly dependent on Fc receptor on host cells. Based on these data and other recent publications on the subject, we propose that anti-human CTLA-4 antibodies induce tumor rejection by selective depletion of Tregs in the tumors rather than blockade of B7-CTLA-4 interaction in lymphoid organs. More... »

PAGES

30

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13578-018-0229-z

DOI

http://dx.doi.org/10.1186/s13578-018-0229-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103452662

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29713453


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Maryland, Baltimore", 
          "id": "https://www.grid.ac/institutes/grid.411024.2", 
          "name": [
            "Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tang", 
        "givenName": "Fei", 
        "id": "sg:person.01242576034.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242576034.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Maryland, Baltimore", 
          "id": "https://www.grid.ac/institutes/grid.411024.2", 
          "name": [
            "Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Du", 
        "givenName": "Xuexiang", 
        "id": "sg:person.011534352000.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011534352000.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Maryland, Baltimore", 
          "id": "https://www.grid.ac/institutes/grid.411024.2", 
          "name": [
            "Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Mingyue", 
        "id": "sg:person.013127313000.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013127313000.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "OncoImmune (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417460.0", 
          "name": [
            "Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA", 
            "OncoImmune, Inc., 9430 Key West Avenue, 20850, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zheng", 
        "givenName": "Pan", 
        "id": "sg:person.011776060217.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011776060217.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "OncoImmune (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417460.0", 
          "name": [
            "Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA", 
            "OncoImmune, Inc., 9430 Key West Avenue, 20850, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Yang", 
        "id": "sg:person.015554657644.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015554657644.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1084/jem.20130573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025992711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-13-0013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027403606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-2776(06)90008-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037003471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-07-2561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037363769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1084/jem.20130579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039859570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-06-2298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042865724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.171.11.6251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076602222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41422-018-0011-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101165607", 
          "https://doi.org/10.1038/s41422-018-0011-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41422-018-0011-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101165607", 
          "https://doi.org/10.1038/s41422-018-0011-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41422-018-0011-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101165607", 
          "https://doi.org/10.1038/s41422-018-0011-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of na\u00efve T cells in the lymphoid organs. Recently, we reported that anti-CTLA-4 antibody Ipilimumab effectively induces tumor rejection in vivo although it blocks neither B7 transendocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Using genetic model in which the anti-CTLA-4 antibodies are unable to engage more than 50% of CTLA-4, we demonstrated that saturating binding of CTLA-4 is not necessary for tumor rejection. Our results argue against B7-CTLA-4 blockade as the mechanism of action for the clinically effective Ipilimumab. Moreover, Ipilimumab induces tumor rejection even in the absence of de novo T cell priming in the lymphoid organs. Thus, our data are inconsistent with key provisions of the prevailing hypothesis on mechanism of action by anti-CTLA-4 antibodies. Furthermore, anti-CTLA-4 antibodies effectively induce depletion of regulatory T (Treg) cells in tumor microenvironment but not in the peripheral lymphoid organs, which is strictly dependent on Fc receptor on host cells. Based on these data and other recent publications on the subject, we propose that anti-human CTLA-4 antibodies induce tumor rejection by selective depletion of Tregs in the tumors rather than blockade of B7-CTLA-4 interaction in lymphoid organs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13578-018-0229-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2457087", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2482137", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2448699", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1045176", 
        "issn": [
          "2045-3701"
        ], 
        "name": "Cell & Bioscience", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?", 
    "pagination": "30", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "13a3f88abb4b69b2f1b673abbaf377c5926e8d5aacb981a4d36c877e94bccbfd"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29713453"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101561195"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13578-018-0229-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103452662"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13578-018-0229-z", 
      "https://app.dimensions.ai/details/publication/pub.1103452662"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99806_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13578-018-0229-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13578-018-0229-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13578-018-0229-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13578-018-0229-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13578-018-0229-z'


 

This table displays all metadata directly associated to this object as RDF triples.

131 TRIPLES      21 PREDICATES      37 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13578-018-0229-z schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author N7849328a49524113988160cfcef4cbe0
4 schema:citation sg:pub.10.1038/s41422-018-0011-0
5 https://doi.org/10.1016/s0065-2776(06)90008-x
6 https://doi.org/10.1084/jem.20130573
7 https://doi.org/10.1084/jem.20130579
8 https://doi.org/10.1158/2326-6066.cir-13-0013
9 https://doi.org/10.1182/blood-2004-07-2561
10 https://doi.org/10.1182/blood-2005-06-2298
11 https://doi.org/10.4049/jimmunol.171.11.6251
12 schema:datePublished 2018-12
13 schema:datePublishedReg 2018-12-01
14 schema:description Antibodies to human CTLA-4 have been shown to induce long-lasting protection against melanoma. It is assumed that these antibodies cause tumor rejection by blocking negative signaling from the B7-CTLA-4 interactions to enhance priming of naïve T cells in the lymphoid organs. Recently, we reported that anti-CTLA-4 antibody Ipilimumab effectively induces tumor rejection in vivo although it blocks neither B7 transendocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Using genetic model in which the anti-CTLA-4 antibodies are unable to engage more than 50% of CTLA-4, we demonstrated that saturating binding of CTLA-4 is not necessary for tumor rejection. Our results argue against B7-CTLA-4 blockade as the mechanism of action for the clinically effective Ipilimumab. Moreover, Ipilimumab induces tumor rejection even in the absence of de novo T cell priming in the lymphoid organs. Thus, our data are inconsistent with key provisions of the prevailing hypothesis on mechanism of action by anti-CTLA-4 antibodies. Furthermore, anti-CTLA-4 antibodies effectively induce depletion of regulatory T (Treg) cells in tumor microenvironment but not in the peripheral lymphoid organs, which is strictly dependent on Fc receptor on host cells. Based on these data and other recent publications on the subject, we propose that anti-human CTLA-4 antibodies induce tumor rejection by selective depletion of Tregs in the tumors rather than blockade of B7-CTLA-4 interaction in lymphoid organs.
15 schema:genre research_article
16 schema:inLanguage en
17 schema:isAccessibleForFree true
18 schema:isPartOf N6fadd0cd34774d64bd08c20848c2b96c
19 Nabbfd5c195454ca3b9f5cb4975c36933
20 sg:journal.1045176
21 schema:name Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
22 schema:pagination 30
23 schema:productId N2f0ef444442d451e8cbe7651c6b378af
24 N45f6d19e8bf6448585fd67c8ae50f749
25 N63a8d91d406b4adf83f9ef3ae04f6125
26 Nae36d73919f34beebb9f91be16d885c9
27 Nfbced9424bcc41baac209b3469a0855e
28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103452662
29 https://doi.org/10.1186/s13578-018-0229-z
30 schema:sdDatePublished 2019-04-11T09:32
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher N2e1aa65b5da64e93b7f9cd67019fa8e1
33 schema:url https://link.springer.com/10.1186%2Fs13578-018-0229-z
34 sgo:license sg:explorer/license/
35 sgo:sdDataset articles
36 rdf:type schema:ScholarlyArticle
37 N073857bae87f400bb2abe9ad42af84d5 rdf:first sg:person.011534352000.33
38 rdf:rest N5782f8ab50d44b85a7bc9c3c15113c31
39 N2e1aa65b5da64e93b7f9cd67019fa8e1 schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 N2f0ef444442d451e8cbe7651c6b378af schema:name readcube_id
42 schema:value 13a3f88abb4b69b2f1b673abbaf377c5926e8d5aacb981a4d36c877e94bccbfd
43 rdf:type schema:PropertyValue
44 N45f6d19e8bf6448585fd67c8ae50f749 schema:name dimensions_id
45 schema:value pub.1103452662
46 rdf:type schema:PropertyValue
47 N564f1795c15a42daa5e18cde4573c6e7 rdf:first sg:person.015554657644.90
48 rdf:rest rdf:nil
49 N5782f8ab50d44b85a7bc9c3c15113c31 rdf:first sg:person.013127313000.36
50 rdf:rest N61c52efe053943f8a8f933dc64d786ac
51 N61c52efe053943f8a8f933dc64d786ac rdf:first sg:person.011776060217.95
52 rdf:rest N564f1795c15a42daa5e18cde4573c6e7
53 N63a8d91d406b4adf83f9ef3ae04f6125 schema:name doi
54 schema:value 10.1186/s13578-018-0229-z
55 rdf:type schema:PropertyValue
56 N6fadd0cd34774d64bd08c20848c2b96c schema:issueNumber 1
57 rdf:type schema:PublicationIssue
58 N7849328a49524113988160cfcef4cbe0 rdf:first sg:person.01242576034.93
59 rdf:rest N073857bae87f400bb2abe9ad42af84d5
60 Nabbfd5c195454ca3b9f5cb4975c36933 schema:volumeNumber 8
61 rdf:type schema:PublicationVolume
62 Nae36d73919f34beebb9f91be16d885c9 schema:name nlm_unique_id
63 schema:value 101561195
64 rdf:type schema:PropertyValue
65 Nfbced9424bcc41baac209b3469a0855e schema:name pubmed_id
66 schema:value 29713453
67 rdf:type schema:PropertyValue
68 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
69 schema:name Medical and Health Sciences
70 rdf:type schema:DefinedTerm
71 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
72 schema:name Immunology
73 rdf:type schema:DefinedTerm
74 sg:grant.2448699 http://pending.schema.org/fundedItem sg:pub.10.1186/s13578-018-0229-z
75 rdf:type schema:MonetaryGrant
76 sg:grant.2457087 http://pending.schema.org/fundedItem sg:pub.10.1186/s13578-018-0229-z
77 rdf:type schema:MonetaryGrant
78 sg:grant.2482137 http://pending.schema.org/fundedItem sg:pub.10.1186/s13578-018-0229-z
79 rdf:type schema:MonetaryGrant
80 sg:journal.1045176 schema:issn 2045-3701
81 schema:name Cell & Bioscience
82 rdf:type schema:Periodical
83 sg:person.011534352000.33 schema:affiliation https://www.grid.ac/institutes/grid.411024.2
84 schema:familyName Du
85 schema:givenName Xuexiang
86 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011534352000.33
87 rdf:type schema:Person
88 sg:person.011776060217.95 schema:affiliation https://www.grid.ac/institutes/grid.417460.0
89 schema:familyName Zheng
90 schema:givenName Pan
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011776060217.95
92 rdf:type schema:Person
93 sg:person.01242576034.93 schema:affiliation https://www.grid.ac/institutes/grid.411024.2
94 schema:familyName Tang
95 schema:givenName Fei
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242576034.93
97 rdf:type schema:Person
98 sg:person.013127313000.36 schema:affiliation https://www.grid.ac/institutes/grid.411024.2
99 schema:familyName Liu
100 schema:givenName Mingyue
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013127313000.36
102 rdf:type schema:Person
103 sg:person.015554657644.90 schema:affiliation https://www.grid.ac/institutes/grid.417460.0
104 schema:familyName Liu
105 schema:givenName Yang
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015554657644.90
107 rdf:type schema:Person
108 sg:pub.10.1038/s41422-018-0011-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101165607
109 https://doi.org/10.1038/s41422-018-0011-0
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/s0065-2776(06)90008-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037003471
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1084/jem.20130573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025992711
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1084/jem.20130579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039859570
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1158/2326-6066.cir-13-0013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027403606
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1182/blood-2004-07-2561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037363769
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1182/blood-2005-06-2298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042865724
122 rdf:type schema:CreativeWork
123 https://doi.org/10.4049/jimmunol.171.11.6251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076602222
124 rdf:type schema:CreativeWork
125 https://www.grid.ac/institutes/grid.411024.2 schema:alternateName University of Maryland, Baltimore
126 schema:name Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA
127 rdf:type schema:Organization
128 https://www.grid.ac/institutes/grid.417460.0 schema:alternateName OncoImmune (United States)
129 schema:name Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, 725 W Lombard Street, 21201, Baltimore, MD, USA
130 OncoImmune, Inc., 9430 Key West Avenue, 20850, Rockville, MD, USA
131 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...